[Statement: cancer treatments and ovarian reserve]

J Gynecol Obstet Biol Reprod (Paris). 2010 Oct;39(6):433-43. doi: 10.1016/j.jgyn.2010.05.012. Epub 2010 Jul 31.
[Article in French]

Abstract

Purpose of review: The purpose of this review is to update the reader on the impact of cancer treatment on fertility, the options of fertility preservation, and the new markers to assess ovarian function.

Essential points: The impact of chemotherapy and radiotherapy on fertility depends on the drugs and the doses used. It often affects ovarian reserve significantly, and the presence of menstruation is not a reliable reflection of it. Fertility preservation techniques, such as ovarian protection, and preferably cryopreservation combined with assisted reproductive medicine, should be individually discussed and possibly proposed to the patients. The use of new markers for ovarian reserve assessment will help to evaluate infraclinic chemotherapy and/or radiotherapy-induced effects on ovarian reserve, prior to clinical effects.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Anti-Mullerian Hormone / blood
  • Anti-Mullerian Hormone / physiology
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Biomarkers
  • Cryopreservation / methods
  • Female
  • Fertility*
  • Gonadotropin-Releasing Hormone / agonists
  • Humans
  • Infertility, Female / etiology
  • Infertility, Female / prevention & control*
  • Neoplasms / drug therapy
  • Neoplasms / radiotherapy
  • Neoplasms / therapy*
  • Ovary / drug effects*
  • Ovary / physiology
  • Ovary / radiation effects*
  • Reproductive Techniques, Assisted

Substances

  • Antineoplastic Agents
  • Biomarkers
  • Gonadotropin-Releasing Hormone
  • Anti-Mullerian Hormone